Abstract
Purpose
Young premenopausal women develop breast cancer (BC) within 5–10 years of the last childbirth, known as post-partum breast cancers (PPBC), often present with aggressive disease. The exact mechanisms that lead to poor prognosis in these patients are largely unknown.
Methods
We have evaluated the association of clinical and reproductive factors with BC in a cohort of women ≤ 45 years (N = 155) with long-term follow-up. Based on duration since last childbirth (LCB), grouped patients into PPBC1 (LCB ≤ 5 years), PPBC2 (LCB between 6 and 10 years), PPBC3 (LCB > 10 years), and NPBC (age-matched nulliparous BC patients). We compared disease-free survival and hazard associated with recurrence/metastasis between the groups. RNA sequencing of tumor samples was performed from three parous groups (n = 10), and transcriptomic data were analyzed for differentially expressed genes and altered pathways.
Results
Women in the PPBC1 group had an early menarche and late age at first and last childbirth compared to other groups. Survival analysis within lymph node-positive tumors showed that PPBC1 tumors had a worse prognosis than PPBC2 and NPBC tumors (p = 0.015 and p = 0.026, respectively). Clustering of the differentially expressed genes between the groups showed distinct expression in early PPBC (E-PPBC) tumors. Pathway analysis revealed upregulation of invasive-related pathways along with T cell exhaustion, extracellular matrix remodeling, angiogenesis, and epithelial-to-mesenchymal transition in E-PPBC tumors.
Conclusion
Early PPBC is a unique subtype with aggressive clinical features and distinct biology. Further research is needed to accurately project the risk of recurrence and optimal treatment strategies in these young patients.
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Introduction
Breast cancer (BC) is the most prevalent cancer and the leading cause of cancer-related deaths and morbidity among women worldwide. The proportion of cancer in young premenopausal women with BC is higher in low–middle-income countries probably due to changes in lifestyle and reproductive factors [1, 2]. Delays in pregnancy and older age at childbirth are associated with the early onset of BC. Previous literature shows that BC in younger women is usually associated with aggressive clinical features compared to BC in the older population [3, 4]. Aggressive disease associated with higher morbidity and mortality in the younger population poses a substantial public health problem.
Some of the unique subtypes of BC confined only to young women in the premenopausal age group are pregnancy-associated BC which develops during pregnancy and post-partum breast cancer (PPBC), which extends up to 10 years after the recent childbirth. Studies have shown a transient increase in the BC risk during early post-partum period, compared to age-matched nulliparous BC patients [5, 6]. Previous studies have reported that BC diagnosed in early post-partum duration is more aggressive than diagnosed during pregnancy [7, 8]. PPBC is associated with a threefold increase in metastasis and death related to BC [8, 9], affecting approximately one-third or more of younger women with BC globally. Despite such a huge burden, PPBC is not yet considered a distinct class of BC. Tumor staging and biologic subtyping alone may be insufficient to accurately assess the risk of recurrence and optimal treatment strategies in young premenopausal patients with BC.
Post-partum mammary gland involution is mainly investigated in animal models. Apoptosis-induced cell death and extracellular matrix (ECM) remodeling, like wound healing, are known mechanisms of involution. Rodent model studies have demonstrated that during post-partum involution, the ECM is enriched in collagen, fibronectin fragments, and matrix metalloproteinases (MMPs), contributing to increased invasion and metastatic potential of tumor cells [10,11,12,13]. Distinct patterns of immune infiltration in PPBC patients compared to nulliparous BC patients suggest an immunosuppressive microenvironment that might contribute to early disease progression [14]. The exact mechanism that leads to poor prognosis in PPBC in humans is unknown.
In the current study, we assessed the tumor characteristics and risk associated with developing PPBC in women ≤ 45 years of age, grouped them based on post-partum duration compared to nulliparous BC patients. We further evaluated differential biological pathways between early (1–5 years) and late post-partum (> 6 years) within age-matched BC patients.
Materials and methods
Patient cohort
The study included a retrospective hospital-based cohort of 155 primary BC patients of age ≤ 45 years who did not receive any prior treatment were recruited for the study from two tertiary cancer care hospitals in Bangalore, India. The diagnosis of BC was confirmed histologically. The maximum follow-up duration was 102 months, with a total loss to follow-up of less than 4% and median follow-up duration of 55 months. The institutional ethical review board approved the study. Informed consent was obtained from all the patients. All the clinical and histopathological information was obtained from the patient’s clinical records. Age at menarche, first childbirth (FCB), and last childbirth (LCB) were collected from medical records or were documented based on specific interrogations with the patients. Patients associated with ambiguous data regarding childbirth were excluded from the study. Information regarding treatment and progression of the disease or disease-related events was obtained during follow-up.
The study cohort was subdivided into four subgroups: PPBC1 (PPBC with LCB ≤ 5 years), PPBC2 (PPBC with LCB between 6 and 10 years), PPBC3 (PPBC with LCB > 10 years), and NPBC (age-matched nulliparous BC patients).
Details of the methods used for RNA sequencing, data processing, functional enrichment analysis, and statistical analysis are mentioned in Additional file 1.
Results
We accessed women with BC aged ≤ 45 years from a retrospective series of 777 tumors. Among these, 155 (20%) were ≤ 45 years with a mean age ± SD of 38.9 ± 5 years. 48% had tumors size > 3 cm and nearly half (45%) were grade 3. Most tumors were lymph node positive (60%) and had a higher proportion of triple-negative BC (29%).
Categorization based on the time since LCB showed 15% (23/155) were within the first 5 years (PPBC1), 25% (38/155) were between 6 and 10 years (PPBC2), 46% (72/155) had tumors 10 years after most recent childbirth (PPBC3), and 14% (22/155) were NPBC.
Association of reproductive and clinicopathological features among different groups
Examination of the association of reproductive features between the 3 PPBC groups showed PPBC1 patients had a significantly older age at FCB and LCB compared to PPBC2 and PPBC3 (FCB, p = 0.007 and p < 0.0001; LCB, p = 0.020 and p < 0.0001, respectively). We also noticed that PPBC2 patients had significantly higher age at FCB and LCB than PPBC3 patients (FCB, p = 0.003; LCB, p < 0.001). In addition, within the PPBC1 group, 91% of patients were comparatively younger at menarche (Fisher exact test, p = 0.047). No association with the number of live births (calculated as parity) was observed among the parous groups. Results are represented in Table 1. There was no association with the family history of BC.
Next, we examined the differences in clinicopathological characteristics such as tumor size, grade, lymph node status, lymphovascular invasion, the density of tumor-infiltrating lymphocytes, estrogen receptor, progesterone receptor, and HER2 status between the parous and nulliparous groups. No significant difference was observed among the groups (Supplementary Table 1, Additional file 1).
Association of post-partum tumors with prognosis
Further, we examined the disease-free survival between the parous and nulliparous groups. 141/155 (91%) had complete follow-up information, with the longest and shortest of 102 and 19 months, respectively. Kaplan–Meier survival analysis showed no difference between parous and nulliparous groups (mean survival time ± SD, 72.6 ± 3.3 vs 68.5 ± 4 months, log-rank test, p = 0.52). Similarly, no difference in survival probability was observed between the PPBC subgroups and NPBC (mean survival time ± SD for PPBC1, PPBC2, PPBC3, and NPBC was 61.8 ± 8.2, 71.3 ± 3.7, 68.9 ± 4 and, 68.5 ± 4 months, respectively, log-rank, p = 0.314) (Fig. 1A).
Next, we performed subset analysis within lymph node-positive tumors alone. 78/141 (56%) were lymph node-positive. Among these, PPBC1 patients (n = 14) had a worse prognosis compared to PPBC2 (n = 20) and NPBC (n = 9) patients (p = 0.015 and p = 0.026 and mean survival time ± SD for PPBC1, PPBC2, and NPBC was 40.2 ± 2.7, 65.3 ± 5, and 64.3 ± 5.5 months, respectively). Similarly, PPBC3 patients (n = 35) had better survival (mean survival time ± SD = 60.3 ± 6 months) compared to PPBC1 patients although not statistically significant (p = 0.60) (Fig. 1B).
In concordance with the Kaplan–Meier analysis within lymph node-positive tumors, cox proportional hazard analysis showed that PPBC1 tumors had a higher hazard ratio compared to PPBC2 tumors [HR = 4.83 (95% CI = 1.12–19.61) (p = 0.028)] and NPBC tumors [HR = 5.30 (95% CI − 1.006 to 27.92) (p = 0.049)] on univariate analysis and [HR = 4.91 (95% CI − 0.68 to 35.13) (p = 0.11)] on multivariate analysis.
Differentially regulated pathways between early and late post-partum groups
Further, to understand the biology of tumors in the early and late post-partum period, we carried out RNA sequencing of the PPBC1 (n = 3), PPBC2 (n = 3) and PPBC3 (n = 4) tumor samples. The clinical characteristics of these ten tumors are mentioned in supplementary table 2 (Additional file 1). We obtained 587 DEGs between PPBC1 vs PPBC2 (280 genes upregulated and 307 genes downregulated). Similarly, 894 DEGs were identified between PPBC1 vs PPBC3 (435 genes upregulated, 459 genes downregulated). Unsupervised hierarchical clustering of these ten tumors showed a distinct separation of 8 tumors into three PPBC groups (Fig. 2A). In addition, these samples clustered better based on post-partum duration than ER status or the molecular subtypes (Supplementary Fig. S1, Additional file 1), suggesting that the post-partum period significantly impacts tumor gene expression.
Further, to understand the expression of genes that are concurrently expressed and regulated in the post-partum period since the LCB, we compared the DEGs between PPBC1 vs PPBC2 and PPBC1 vs PPBC3 (Supplementary Fig. S2, Additional file 1). We identified 178 DEGs that were common and overlapping between the groups. Unsupervised hierarchical clustering showed that the expression pattern of these selected DEGs was similar in PPBC2 and PPBC3 (Supplementary Fig. S3A, Additional file 1), and the PPBC1 tumors had a distinct pattern compared to the others. Further, PPBC1 tumors clustered separately in principal component analysis (PCA) (Supplementary Fig. S3B, Additional file 1) from the other two groups (PPBC2 and PPBC3). These results indicated that the post-partum tumors in the immediate vicinity of 5 years, since the LCB were distinctly different in their gene expression from those in the later post-partum period. Hence, we labeled PPBC1 as early PPBC (E-PPBC, post-partum period ≤ 5 years) and PPBC2 and PPBC3 tumors were combined and regrouped as late PPBC tumors (L-PPBC, post-partum duration > 6 years) for further analysis.
Next, we checked the differential pathways regulated between E-PPBC and L-PPBC tumors. There were 745 DEGs between the two groups (287 DEGs were upregulated and 458 DEGs were downregulated). Functional enrichment analysis demonstrated that the E-PPBC tumors were enriched in immune-related processes, ECM organization/degradation, and tumor cell invasion. Gene ontology-based analysis showed that E-PPBC compared to L-PPBC tumors were enriched for immune-related terms, such as leucocyte/lymphocyte/T cell activation, innate and adaptive immune response, and cytokine-mediated signaling, among others. Apart from the immune-related terms, we observed other upregulated processes related to angiogenesis, ECM organization, cell migration, wound healing, and BMP signaling. On the other hand, downregulated processes were cell morphogenesis and differentiation, cell adhesion, ion transport, lipid metabolic processes, response to estrogen and progesterone, regulation of MAPK cascade, and ERBB2-ERBB3 signaling pathway. Figure 2B represents major differentially regulated biological processes in E-PPBC compared to L-PPBC. Curated pathway analysis by GSEA showed that E-PPBC were enriched in tumor invasion along with ECM and its component degradation. In line with the gene ontology analysis, pathways related to cell cycle, DNA repair, and response to steroid hormones were downregulated (Fig. 2C).
To examine if the biological processes observed through gene ontologies were related to the involution process during the normal post-partum period, we obtained gene expression data from normal breast [15] at various time points after childbirth. Based on the time since the LCB, we categorized them into early and late post-partum periods using a similar cut-off of ≤ 5 years. We noticed that most gene ontologies, such as immune-related pathways, cell adhesion, response to steroid hormones, ERBB signaling, cell differentiation and morphogenesis, and angiogenesis were among the commonly enriched ontologies specific to early post-partum duration irrespective of cancerous and non-cancerous conditions (Supplementary Fig. S4, Additional file 1). The major differences observed in the early post-partum period in cancerous conditions were upregulation of angiogenesis, enrichment of macrophage markers, interleukins 4 and 13 signaling, cell migration, and wound healing.
Estimation of immune cell subtypes between the E-PPBC and L-PPBC groups
As GSEA analysis showed predominant upregulation of immune-related pathways in E-PPBC tumors compared to L-PPBC, we examined the immune cell subtypes within each group of tumors. We estimated the immune cell infiltration between the groups using deconvolution-based methods using CIBERSORT, xCell, EPIC, MCP-counter, and quanTIseq. Estimating the cell components is important to understand the distinct tumor immune microenvironment. Comparison of the cell types between the two groups showed that the significantly higher cell types (p < 0.05) in E-PPBC were M0 (CIBERSORT, xCell, MCP-counter), M1 (xCell, quanTIseq) and M2 (xCell) macrophages, and natural killer cells (xCell, EPIC). The proportion of immature dendritic cells (xCell) was significantly (p < 0.05) reduced in E-PPBC tumor samples. The distribution of M0 macrophages in E-PPBC and L-PPBC tumors is represented in Fig. 3A. Further, the proportion of tumor-associated macrophages (TAM) between E-PPBC and L-PPBC tumors was analyzed using 36 gene TAM signatures [16] (Fig. 3B). The distribution of other cell types did not differ between the two groups.
The analysis of differential pathways showed that T cell activation, proliferation, and differentiation were significantly upregulated (Fig. 2B) in E-PPBC tumors. To assess the T cell functionality, we used the T cell exhaustion signature (PD-1, PDL1, PDL2, CTLA4, TIGIT, IDO1, IDO2, and TIM3) [17]. A comparison of the score distribution between the two groups showed E-PPBC tumors had significantly higher T cell exhaustion scores suggesting that these tumors are likely to have pro-tumorigenic microenvironment (Fig. 3C).
Alterations in key pathways involved in tumor progression in E-PPBC
We further examined important cancer hallmark pathways contributing to an aggressive disease, such as ECM remodeling, angiogenesis, epithelial-to-mesenchymal transition (EMT), hypoxia, and stem cell phenotype, using the pathway-specific genes from the molecular signature database. The DEGs mapped with the signature gene sets are mentioned in supplementary Table 3 (Additional file 1). We evaluated ECM remodeling between E-PPBC and L-PPBC groups. DEGs that mapped with selected ECM gene signatures included ECM proteins, ECM regulators, and secreted factors involved in remodeling. E-PPBC tumors were significantly enriched (p = 0.017) in the ECM remodeling signature (Fig. 4A).
Tumor growth and metastasis depend on angiogenesis. As mentioned in Fig. 2B, the regulation of angiogenesis was an upregulated process in E-PPBC by GSEA analysis. We further validated this biological process using the angiogenesis gene signature. There was significantly increased (p = 0.033) angiogenesis in E-PPBC compared to L-PPBC tumors (Fig. 4B). Additionally, we observed E-PPBC tumors were more mesenchymal, which was indicated by a significantly high EMT score (p = 0.036) (Fig. 4C). Further, we also checked expressions of hypoxia-related and stemness gene signatures, and no significant difference was noticed between the two groups.
Invasive nature of the E-PPBC tumors
On enrichment analysis, we identified genes annotated with the term “breast cancer ductal invasive” as being significantly (q = 3 × 10–40) upregulated, followed by “multicancer invasiveness signature” (q = 6.72 × 10–12). The top 10 up- and downregulated pathways enriched using GSEA are represented in Fig. 2C. Enriched terms are given in Additional file 2.
To derive invasion-specific gene signatures in E-PPBC that can predict patient prognosis, 183 leading-edge genes (those genes that “drive” the enrichment score in a GSEA analysis) of “breast cancer ductal invasive” from GSEA analysis were collected. Out of these, 34 upregulated genes overlapped with DEGs of E-PPBC vs L-PPBC. Further, we considered genes falling in the top 25 percentile to derive a smaller subset. Based on this analysis, we derived ten genes, among them nine genes mapped with a public database (METABRIC) (listed in supplementary Table 4, Additional file 1). The gene score was calculated based on the average expression of these nine genes across all samples. We categorized the tumors into high- and low-expression groups using a mean score. Examination of the relapse-free survival in external datasets (METABRIC) in women ≤ 45 years showed tumors with high invasive score had poor survival (mean survival time, high vs low overall survival, 122 vs 99 months, p = 0.046 and relapse-free survival, 117 vs 88 months, p = 0.023) (Fig. 5). These results further confirmed that invasive signature derived from E-PPBC is associated with poor prognosis.
To check if the gene signature would vary by subtype of breast cancer, we examined the pattern of expression of these genes in tumors (n = 10). Further subgrouping was identified by the IHC classification and PAM50 subtypes. Supplementary Fig. S5A (Additional File 1) shows the distribution of the tumors within the subclasses. As seen in the figure, distribution of the genes was clearly different between E-PPBC and L-PPBC and not different between ER + and TNBC tumors. PAM50 subtypes were also distributed in both E-PPBC and L-PPBC tumors without any subtype specificity. We further explored a larger set of tumors, [METABRIC, less than ≤ 45 years (n = 248)] and examined the expression of nine chosen genes in these tumors. Tumors were divided into invasive signature high and low (based on median value of mean of 9 genes) due to the lack of information on LCB. Clear pattern emerged between gene signature high and low tumors (Supplementary Fig. S5B, Additional File 1), while no pattern was visible by the ER + /TNBC classes or PAM50 subtypes. These results indicate that invasive signature does not vary by the subtype of the tumors.
Discussion
Epidemiological studies have demonstrated the dual role of pregnancy on the risk of BC in a time-dependent manner. The risk of BC increases transiently after pregnancy, followed by a period of long-term protection [5, 18]. Involution-associated changes in the mammary gland post-pregnancy induce a pro-tumorigenic environment favorable for tumor development. As these changes are more pronounced during the E-PPBC, we examined the changes in the biological pathways altered in E-PPBC compared to those in L-PPBC. In line with other large cohort studies [19, 20], our findings show an increased risk of metastasis in BC patients within 1–5 years of post-partum duration. Early menarche and older age at first and last childbirth were observed in E-PPBC tumors compared to other groups. No differences were observed for various clinicopathological characteristics among PPBC and NPBC patients in concurrence with previous studies, indicating no selection bias. Earlier reports have shown PPBC tends to have more lymph node-positive disease [19, 21]. Similarly, we also found a poor prognosis confined to lymph node-positive BC patients. Our results confirm post-partum duration as an independent prognostic factor and should be factored into the clinical care of young women with BC.
Gene expression studies done previously in PPBC have compared parous to nulliparous breast tissue in normal as well as cancerous conditions [14, 15, 22] without much emphasis on differentially regulated pathways and biological processes between E-PPBC and L-PPBC. Pereira et al. reported that transient genes upregulated in the normal early post-partum period were mainly immune response genes. In contrast, genes that remained upregulated in the late post-partum period were mainly involved in development/differentiation. We found similar results, showing upregulation of immune-related signaling in E-PPBC and differentiation and morphogenesis-related pathways in L-PPBC. Comparison of gene expression patterns between the normal post-partum period and E-PPBC showed enrichment for similar gene ontology terms indicating these biological processes were specific to early post-partum changes [15]. Other studies have characterized immune cell infiltration in involuting normal breast tissue and reported a transient increase in the immunosuppressed microenvironment [10, 23, 24]. In concordance with these studies, we observed increased expression of T cell exhaustion signatures in E-PPBC tumors indicating a higher proportion of the non-responsive T cell population supportive of the immunosuppressive tumor microenvironment.
We have examined hallmark pathways involved in cancer development and progressions, such as ECM remodeling, angiogenesis, and EMT, and observed they were upregulated in E-PPBC tumors. ECM remodeling is an important mechanism in tumor growth, differentiation, migration, and invasion [25]. ECM components are chemotactic and attract endothelial and immune cells, such as macrophages and neutrophils [26]. EMT and angiogenesis are two other critical processes influencing tumor growth and metastasis. Alteration in these pathways paves the way for tumor cell invasion, which is the first key step in the metastatic cascade of tumors.
Evaluating invasive signatures in BC is mostly confined to identifying ductal carcinoma in situ for its invasive potential [27,28,29]. Development of clinically relevant human invasive signatures (HIS) using metastasizing tumor cells have been attempted [30,31,32,33]. These signatures were enriched in genes that regulate embryonic development, EMT, DNA replication, repair, and resistance to treatment providing mechanistic insights into BC invasion and metastasis [30, 31]. In the current study, we have identified invasive signature in E-PPBC tumors from transcriptomic analysis of whole tumor samples. Analysis of the differentially regulated genes between the E-PPBC and L-PPBC in our study showed ‘breast cancer invasive’ and ‘multicancer invasive’ as the topmost enriched terminologies, followed by ECM organization and degradation, among the other enriched pathways. We then derived an invasive signature from the top quartile of the highly enriched pathway that was differentially regulated between E-PPBC and L-PPBC. These genes were mainly involved in regulating ECM remodeling, cell adhesion, migration, EMT and immune/inflammatory functions. The derived invasive signature’s ability to differentiate overall and relapse-free survival in women ≤ 45 years from public datasets further confirms the enrichment of invasive phenotype in E-PPBC tumors.
Identifying invasive phenotype in E-PPBC may have important biological and therapeutic implications. Firstly, gene expression profile-based tests may not accurately identify risk in these tumors [34,35,36] as these tests are heavily biased with a predominance of proliferation-associated genes. While we identified invasive pathways upregulated in E-PPBC, our analysis did not find any difference in the expression of proliferation genes between the groups. Earlier studies have shown that the invasive cancer cell population is characterized by downregulation of proliferation and cell cycle genes while upregulation of motility, invasion, and DNA repair genes [30]. Our analysis showed that PAM50-based subtyping of these tumors also partially overlapped with the IHC-based classes, further confirming the inaccuracy of existing methods for identifying molecular heterogeneity of these tumors. Secondly, commonly used cytotoxic chemotherapeutic agents in neoadjuvant settings have previously been shown to induce cell damage and inflammatory wound healing, promoting cell invasion and metastatic dissemination [37]. Given these facts, treating E-PPBC tumors with neoadjuvant chemotherapy can potentially act as an accelerator for the metastatic process contributing to poor prognosis despite being treated with currently accepted therapeutic guidelines. This hypothesis needs to be carefully examined further in clinical trials. Whether these tumors might respond to immunotherapy is speculative at this point. Our analysis showed the higher presence of exhausted T cells in the aggressive E-PPBC tumors suggesting tumorigenic environment. Recent studies indicate the presence of subpopulations of precursor exhausted T cells within the exhausted T cells which respond better to immune check point inhibitors [38, 39]. Further exploration and detailed molecular profiling are necessary to identify tumors enriched for these cellular compositions to derive benefit from immunotherapy for PPBC tumors.
The small numbers limit our study for clinical data analysis and exploration of biological pathways. With the limited number of fresh frozen samples that qualified for in-depth RNA sequencing, we could not perform subtype-specific analysis. The proportion of ER-positive and -negative tumors across three PPBC groups was also variable. However, no correlation was found between IHC subtypes and PPBC groups, indicating our analysis is unlikely to be biased by including both ER-positive and -negative tumors. Additionally, unsupervised hierarchical clustering grouped samples better based on post-partum duration rather than tumor subtype or ER status. The lack of carefully documented information on age at last childbirth in large public datasets prevents identifying PPBC tumors and exploring our findings in other series. Multiple institute-based collaborative efforts are required to conduct specific PPBC cohort studies to validate our findings further.
Conclusion
Our study reiterates the association of E-PPBC with poor prognosis. Further, it demonstrates that it is characterized by immunomodulation and alterations in several key hallmark pathways favoring tumor cell invasion and leading to early metastasis in these tumors. Understanding the mechanisms of tumor promotion that occur in the post-partum duration will lead to the development of treatment and, possibly, effective prevention strategies for young premenopausal women. We emphasize that the time since recent childbirth should be considered a prognostic biomarker in premenopausal BC.
Data availability
The datasets generated and analysed during the current study are available in the Gene Expression Omnibus with accession number GSE223470 (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE223470).
Abbreviations
- BC:
-
Breast cancer
- CI:
-
Confidence interval
- DEGs:
-
Differentially expressed genes
- DFS:
-
Disease-free survival
- ECM:
-
Extracellular matrix
- EMT:
-
Epithelial-to-mesenchymal transition
- E-PPBC:
-
Early PPBC
- FCB:
-
First childbirth
- GSEA:
-
Gene set enrichment analysis
- HR:
-
Hazard ratio
- LCB:
-
Last childbirth
- L-PPBC:
-
Late PPBC
- MMPs:
-
Matrix metalloproteinases
- NPBC:
-
Nulliparous breast cancer
- PPBC:
-
Post-partum breast cancer
- TAM:
-
Tumor-associated macrophages
References
Lima SM, Kehm RD, Terry MB (2021) Global breast cancer incidence and mortality trends by region, age-groups, and fertility patterns. EClinicalMedicine 38:100985. https://doi.org/10.1016/j.eclinm.2021.100985
Heer E, Harper A, Escandor N et al (2020) Global burden and trends in premenopausal and postmenopausal breast cancer: a population-based study. Lancet Glob Health 8:e1027–e1037. https://doi.org/10.1016/S2214-109X(20)30215-1
Chollet-Hinton L, Anders CK, Tse CK et al (2016) Breast cancer biologic and etiologic heterogeneity by young age and menopausal status in the Carolina breast cancer study: a case-control study. Breast Cancer Res 18:1–10. https://doi.org/10.1186/s13058-016-0736-y
Fredholm H, Eaker S, Frisell J et al (2009) Breast cancer in young women: Poor survival despite intensive treatment. PLoS ONE 4:1–9. https://doi.org/10.1371/journal.pone.0007695
Liu Q, Wuu J, Lambe M et al (2002) Transient increase in breast cancer risk after giving birth: postpartum period with the highest risk (Sweden). Cancer Causes Control 13:299–305. https://doi.org/10.1023/A:1015287208222
Lambe M, Hsieh C, Trichopoulos D et al (1994) Transient increase in the risk of breast cancer after giving birth. N Engl J Med 331:5–9. https://doi.org/10.1056/NEJM199407073310102
Amant F, Lefrère H, Borges VF et al (2021) The definition of pregnancy-associated breast cancer is outdated and should no longer be used. Lancet Oncol 22:753–754. https://doi.org/10.1016/S1470-2045(21)00183-2
Callihan EB, Gao D, Jindal S et al (2013) Postpartum diagnosis demonstrates a high risk for metastasis and merits an expanded definition of pregnancy-associated breast cancer. Breast Cancer Res Treat 138:549–559. https://doi.org/10.1007/s10549-013-2437-x
Hartman EK, Eslick GD (2016) The prognosis of women diagnosed with breast cancer before, during and after pregnancy: a meta-analysis. Breast Cancer Res Treat 160:347–360. https://doi.org/10.1007/s10549-016-3989-3
O’Brien J, Lyons T, Monks J et al (2010) Alternatively activated macrophages and collagen remodeling characterize the postpartum involuting mammary gland across species. Am J Pathol 176:1241–1255. https://doi.org/10.2353/ajpath.2010.090735
Schedin P, Mitrenga T, McDaniel S, Kaeck M (2004) Mammary ECM Composition and function are altered by reproductive state. Mol Carcinog 41:207–220. https://doi.org/10.1002/mc.20058
Clarkson RWE, Wayland MT, Lee J et al (2004) Gene expression profiling of mammary gland development reveals putative roles for death receptors and immune mediators in post-lactational regression. Breast Cancer Res. https://doi.org/10.1186/bcr754
Tamburini BAJ, Elder AM, Finlon JM et al (2019) PD-1 blockade during post-partum involution reactivates the anti-tumor response and reduces lymphatic vessel density. Front Immunol 10:1313. https://doi.org/10.3389/fimmu.2019.01313
Jindal S, Pennock ND, Sun D et al (2021) Postpartum breast cancer has a distinct molecular profile that predicts poor outcomes. Nat Commun 12:1–15. https://doi.org/10.1038/s41467-021-26505-3
Santucci-Pereira J, Zeleniuch-Jacquotte A, Afanasyeva Y et al (2019) Genomic signature of parity in the breast of premenopausal women. Breast Cancer Res 21:1–19. https://doi.org/10.1186/s13058-019-1128-x
Cassetta L, Fragkogianni S, Sims AH et al (2019) Human tumor-associated macrophage and monocyte transcriptional landscapes reveal cancer-specific reprogramming, biomarkers, and therapeutic targets. Cancer Cell 35:588–602
Wherry EJ, Kurachi M (2015) Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol 15:486–499. https://doi.org/10.1038/nri3862
Lambe M, Hsieh C-C, Trichopoulos D, Ekbom A, Pavia M et al (1994) Transient increase in the risk of breast cancer after giving birth. N Engl J Med 331:1173–1180. https://doi.org/10.1056/NEJM199407073310102
Goddard ET, Bassale S, Schedin T et al (2019) Association between postpartum breast cancer diagnosis and metastasis and the clinical features underlying risk. JAMA Netw Open 2:1–15. https://doi.org/10.1001/jamanetworkopen.2018.6997
Zhang Z, Bassale S, Jindal S et al (2022) Young-Onset breast cancer outcomes by time since recent childbirth in Utah. JAMA Netw Open 5:E2236763. https://doi.org/10.1001/jamanetworkopen.2022.36763
Lyons TR, Borges VF, Betts CB et al (2014) Cyclooxygenase-2-dependent lymphangiogenesis promotes nodal metastasis of postpartum breast cancer. J Clin Investig 124:3901–3912. https://doi.org/10.1172/JCI73777
Asztalos S, Gann PH, Hayes MK et al (2010) Gene expression patterns in the human breast after pregnancy. Cancer Prev Res 3:301–311. https://doi.org/10.1158/1940-6207.CAPR-09-0069
Guo Q, Minnier J, Burchard J et al (2017) Physiologically activated mammary fibroblasts promote postpartum mammary cancer. JCI Insight. https://doi.org/10.1172/jci.insight.89206
Martinson HA, Jindal S, Durand-Rougely C et al (2015) Wound healing-like immune program facilitates postpartum mammary gland involution and tumor progression. Int J Cancer 136:1803–1813. https://doi.org/10.1002/ijc.29181
Bonnans C, Chou J, Werb Z (2014) Nat Rev Mol Cell Biol 15:786–801. https://doi.org/10.1038/nrm3904.Remodelling
McMahon M, Ye S, Pedrina J et al (2021) Extracellular matrix enzymes and immune cell biology. Front Mol Biosci 8:1–9. https://doi.org/10.3389/fmolb.2021.703868
Schuetz CS, Bonin M, Clare SE et al (2006) Progression-specific genes identified by expression profiling of matched ductal carcinomas in situ and invasive breast tumors, combining laser capture microdissection and oligonucleotide microarray analysis. Cancer Res 66:5278–5286. https://doi.org/10.1158/0008-5472.CAN-05-4610
Rebbeck CA, Xian J, Bornelöv S et al (2022) Gene expression signatures of individual ductal carcinoma in situ lesions identify processes and biomarkers associated with progression towards invasive ductal carcinoma. Nat Commun 13:1–14
Karagiannis GS, Goswami S, Jones JG et al (2016) Signatures of breast cancer metastasis at a glance. J Cell Sci 129:1751–1758. https://doi.org/10.1242/jcs.183129
Patsialou A, Wang Y, Lin J et al (2012) Selective gene-expression profiling of migratory tumor cells in vivo predicts clinical outcome in breast cancer patients. Breast Cancer Res. https://doi.org/10.1186/bcr3344
Patsialou A, Bravo-Cordero JJ, Wang Y et al (2013) Intravital multiphoton imaging reveals multicellular streaming as a crucial component of in vivo cell migration in human breast tumors. Intravital 2:e25294. https://doi.org/10.4161/intv.25294
Roussos ET, Balsamo M, Alford SK et al (2011) Mena invasive (Mena INV) promotes multicellular streaming motility and transendothelial migration in a mouse model of breast cancer. J Cell Sci 124:2120–2131. https://doi.org/10.1242/jcs.086231
Wang W, Goswami S, Lapidus K et al (2004) Identification and testing of a gene expression signature of invasive carcinoma cells within primary mammary tumors. Cancer Res 64:8585–8594. https://doi.org/10.1158/0008-5472.CAN-04-1136
Van’t Veer LJ, Dai H, Van De Vijver MJ et al (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415:530–536
Bernard PS, Parker JS, Mullins M et al (2009) Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 27:1160–1167. https://doi.org/10.1200/JCO.2008.18.1370
Soonmyung Paik MD, Steven Shak MD, Gong Tang PhD, Chungyeul Kim MD, Joffre Baker PhD, Maureen Cronin PhD, Baehner FL et al (2004) A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351:2817–2826. https://doi.org/10.1080/14733400500093379
Karagiannis GS, Pastoriza JM, Wang Y et al (2017) Through a TMEM-mediated mechanism. Sci Transl Med 9:1–30. https://doi.org/10.1126/scitranslmed.aan0026.Neoadjuvant
Miller BC, Sen DR, Al Abosy R et al (2019) Subsets of exhausted CD8(+) T cells differentially mediate tumor control and respond to checkpoint blockade. Nat Immunol 20:326–336. https://doi.org/10.1038/s41590-019-0312-6
Kallies A, Zehn D, Utzschneider DT (2020) Precursor exhausted T cells: key to successful immunotherapy? Nat Rev Immunol 20:128–136. https://doi.org/10.1038/s41577-019-0223-7
Acknowledgements
The authors would like to acknowledge Dr TS Sridhar for mentoring JSP and building the cohort with longitudinal follow-up.
Funding
This work was supported by DBT/Wellcome Trust India Alliance Fellowship/Grant [IA/CPHI/18/1/503938] awarded to JSP. Patient recruitment and follow-up activities were supported by philanthropic funding from Nadathur Estates Private Ltd., Bangalore, India and Bagaria Education Trust, Bangalore, India. The authors declare that this study received funding from Nadathur Estates Private Ltd., Bangalore, India and Bagaria Education Trust, Bangalore, India, for patient recruitment and follow-up activities. The funder was not involved in the study design, collection, analysis, interpretation of data, the writing of this article, or the decision to submit it for publication.
Author information
Authors and Affiliations
Contributions
VPN and SR prepared samples for RNA sequencing. SVP analyzed RNA sequencing data. VPN, SVP, and SR performed the statistical analysis. RR and BSS provided all the patient information from their clinics. RK and AA collected data from medical records and patient interactions, along with follow-up and monitoring of the data. VPN and JSP wrote the first draft of the manuscript, and all authors commented on previous versions. JSP was responsible for concept design, statistical analysis, and interpretation. All authors read and approved the final manuscript.
Corresponding author
Ethics declarations
Conflict of interest
The authors have no relevant financial or non-financial interests to disclose.
Ethical approval
The studies involving human participants were reviewed and approved by the institutional ethical committee, St John’s Medical College and Hospital, Bangalore (No. IEC/1/655/2019). The patients/participants provided their written informed consent to participate in this study. This study was performed in line with the principles of the declaration of Helsinki.
Consent for publication
Not applicable.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Nimbalkar, V.P., Snijesh, V.P., Rajarajan, S. et al. Premenopausal women with breast cancer in the early post-partum period show molecular profiles of invasion and are associated with poor prognosis. Breast Cancer Res Treat 200, 139–149 (2023). https://doi.org/10.1007/s10549-023-06956-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10549-023-06956-6